CP 55,940

CP 55,940 is a synthetic cannabinoid which mimics the effects of naturally occurring THC (tetrahydrocannabinol). It was created by the pharmaceutical company Pfizer in 1974. It is considered a full agonist, as it can initiate an intrinsic activity at the cannabinoid receptors CB1 and CB2.

Chemistry

CP 55,940 is a derivative of cannabinol, a metabolite of THC, with a dimethylheptyl side chain. The compound is often used in research due to its potent binding affinity for the cannabinoid receptors. It is classified as a phenol, a type of organic compound that contains a phenolic group.

Pharmacology

CP 55,940 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, but it has more affinity for the CB1 receptor. The CB1 receptor is primarily located in the brain, while the CB2 receptor is found mainly in the immune system. The compound's effects are similar to those of THC, but it is significantly more potent.

Medical Use

While CP 55,940 itself is not used medically, it has been instrumental in the development of a number of medically important drugs. It has been used in research to develop new drugs for the treatment of pain, obesity, and neurological disorders among others.

Legal Status

In the United States, CP 55,940 is a Schedule I controlled substance, which means it has a high potential for abuse and no accepted medical use. It is also controlled under similar laws in many other countries.

See Also

• Cannabinoid
• Cannabinoid receptor
• Tetrahydrocannabinol
• Pfizer